Fast Facts: The 340B Drug Pricing Program
2025 Neurological Disease Working Group Meeting Summary
How PDABs Impede Access
For the First Time, Part B Drugs Part of Price Negotiations
A Historic Leap in Diagnostic Capacity
Parkinson’s Research Brings Promising Developments
Ensuring Early Testing And Treatment In Alzheimer’s Disease
Biomarker Testing in Neurology
Prescription Drug Affordability Boards and Personalized Care
VA Expands Access to Amyloidosis Treatment
